Mainz Biomed N.V. (MYNZ)
NASDAQ: MYNZ · Real-Time Price · USD
3.070
-0.510 (-14.25%)
Mar 31, 2025, 2:14 PM EDT - Market open
Mainz Biomed Revenue
Mainz Biomed had revenue of $260.39K in the quarter ending June 30, 2024, with 4.60% growth. This brings the company's revenue in the last twelve months to $917.20K, up 16.23% year-over-year. In the year 2023, Mainz Biomed had annual revenue of $895.48K with 69.00% growth.
Revenue (ttm)
$917.20K
Revenue Growth
+16.23%
P/S Ratio
1.95
Revenue / Employee
$12,918
Employees
71
Market Cap
10.34M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 895.48K | 365.60K | 69.00% |
Dec 31, 2022 | 529.88K | -47.47K | -8.22% |
Dec 31, 2021 | 577.35K | 83.78K | 16.98% |
Dec 31, 2020 | 493.57K | 212.17K | 75.40% |
Dec 31, 2019 | 281.39K | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 400.28B |
Johnson & Johnson | 88.82B |
Merck & Co. | 64.17B |
AbbVie | 56.33B |
AstraZeneca | 54.07B |
Novartis AG | 51.72B |
Eli Lilly and Company | 45.04B |
Thermo Fisher Scientific | 42.88B |
MYNZ News
- 4 days ago - Mainz Biomed Enrolls First Patient in Its eAArly DETECT 2 Clinical Study - GlobeNewsWire
- 18 days ago - Mainz Biomed and Liquid Biosciences Make Groundbreaking Discovery of mRNA Biomarkers for Blood Based Detection of Pancreatic Cancer - GlobeNewsWire
- 4 weeks ago - Colorectal Cancer Awareness Month: Mainz Biomed Advocates for a Shift from Screening to Prevention - GlobeNewsWire
- 5 weeks ago - Mainz Biomed Expands into Switzerland with labor team w - GlobeNewsWire
- 6 weeks ago - Mainz Biomed and GANZIMMUN Announce Launch of Enhanced ColoAlert Colorectal Cancer Screening Ahead of Awareness Month - GlobeNewsWire
- 2 months ago - Mainz Biomed N.V. Regains Compliance with Nasdaq Capital Market Listing Requirements - GlobeNewsWire
- 2 months ago - Mainz Biomed Initiates U.S. Clinical Study to Evaluate Performance of Next Generation Test on Advanced Adenomas over Large Patient Population - GlobeNewsWire
- 3 months ago - Mainz Biomed Forms Agreement with Quest Diagnostics to Provide Clinical Trials Laboratory Services for Colorectal Cancer Screening Test - GlobeNewsWire